USPTO 2015–2025 USPTO PatentsView Foreign Corporation

ONO Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 155 granted patents across 19 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

155

Total patents granted

CPC technology areas

12.1

Avg claims per patent

-39%

5-year filing velocity

The verdict

ONO holds 155 US patents across 19 technology areas, rank #2,517 of 50,000 tracked assignees.

#2,517
of 50,000 US assignees by volume: Top 28%
by Innovation Score (43.4/100): 12.1
avg claims per patent: -39%
filing velocity, last 5 yrs

Portfolio overview

ONO Pharmaceutical Co., Ltd. has been granted 155 US utility patents between 2015 and 2025, placing ONO Pharmaceutical Co., Ltd. at rank #2,517 across all assignees tracked by PlainPatent. This portfolio spans 19 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, ONO Pharmaceutical Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, ONO sits between Genomatica, Inc. (155 patents, rank #2,513) and Atlassian, Inc. (154 patents, rank #2,521) - the closest US assignees by grant volume. The composite Innovation Score of 43.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 59 grants, compared with 96 in the 2015–2019 window, a -39% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. ONO Pharmaceutical Co., Ltd.'s 12.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 19 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ONO Pharmaceutical Co., Ltd. against peers pursuing similar technology classes.

Genomatica

155
Idemia Identity &…

155
Newport Fab

155
Oce- B V

155
Safran Seats USA

155
Tenneco

155
Wilson Sporting G…

155
ONO Pharmaceutical ◀

155
Atlassian

154

What this shows ONO holds 155 patents at rank #2,517, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near ONO

By rank, the assignees closest to #2,517 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in ONO's primary technology class.

ONO's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

43 Top 28% higher than 72% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

ONO Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	18	11.6%
2016	18	11.6%
2017	18	11.6%
2018	21	13.5%
2019	21	13.5%
2020	17	11.0%
2021	11	7.1%
2022	7	4.5%
2023	7	4.5%
2024	10	6.5%
2025	7	4.5%

Which technologies does ONO Pharmaceutical Co., Ltd. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 150

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 136

C07D - HETEROCYCLIC COMPOUNDS 113

C07K - PEPTIDES 38

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 20

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 20

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 13

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 10

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 5

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 5

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 3

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 2

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 2

C08B - POLYSACCHARIDES; DERIVATIVES THEREOF 2

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 1

Top 15 of 19 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#2,517

Across all tracked assignees

Innovation Score

43.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does ONO Pharmaceutical Co., Ltd. hold?

ONO Pharmaceutical Co., Ltd. holds 155 US granted patents filed between 2015 and 2025, spanning 19 technology areas.

What is ONO Pharmaceutical Co., Ltd.'s Innovation Score?

ONO Pharmaceutical Co., Ltd. has an Innovation Score of 43.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does ONO Pharmaceutical Co., Ltd. focus on?

ONO Pharmaceutical Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 150 patents. The company has filed patents in 19 CPC subclasses total.

Is ONO Pharmaceutical Co., Ltd.'s patent filing rate increasing or decreasing?

ONO Pharmaceutical Co., Ltd.'s recent filing velocity is -39% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for ONO Pharmaceutical Co., Ltd.'s patents?

ONO Pharmaceutical Co., Ltd.'s patents average 12.1 claims each. This falls within the standard range, providing solid legal coverage.

How is the ONO Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

ONO's 155 grants land it in the top 28% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - ONO ranks #2,517 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.